Ocular Therapeutix (OCUL) Interest & Investment Income (2013 - 2026)

Ocular Therapeutix's Interest & Investment Income history runs 14 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 58.13% year-over-year to $6.0 million in Q1 2026; TTM through Mar 2026 was $20.6 million, a 1.94% increase from a year earlier, with the FY2025 full-year figure at $18.4 million, down 9.5% from the prior year.
• Interest & Investment Income fell to $6.0 million in Q1 2026 per OCUL's latest filing, from $7.3 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $7.3 million in Q4 2025 and bottomed at $18000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $3.5 million (2025), against an average of $2.9 million.
• Across the five-year window, Interest & Investment Income soared 6950.0% in 2022 and tumbled 42.76% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $423000.0 in 2022, then jumped by 244.92% to $1.5 million in 2023, then soared by 220.15% to $4.7 million in 2024, then jumped by 57.2% to $7.3 million in 2025, then dropped by 17.61% to $6.0 million in 2026.
• Per Business Quant, the three latest OCUL Interest & Investment Income figures stand at $6.0 million (Q1 2026), $7.3 million (Q4 2025), and $3.7 million (Q3 2025).